Review top news and interview highlights from the week ending August 25, 2023.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Initial data from the combination substudy are expected in the second half of 2023.
The founder, chairman, and CEO of Celularity discussed the advantages of cells derived from umbilical cord blood versus other sources of cells for cell therapies.
Participants treated both unilaterally or bilaterally reported clinically meaningful improvements on GRCQ and XQ scale scores.
The interventional cardiologist and professor, Duke University School of Medicine, discussed how XC001 could improve outcomes for patients with refractory angina.
The company announced that it had completed dosing in the first cohort of the GALILEO-1 trial of FLT201.